New treatment strategies for COPD. Pairing the new with the tried and true.
Knowledge about COPD has increased substantially in recent years. Smoking cessation campaigns have significantly decreased smoking prevalence in the United States, and similar efforts in the rest of the world will likely have the same impact. The consequence should be a drop in incidence of COPD in the years to come. The use of LTOT for hypoxemic patients has resulted in increased survival, and expanded drug therapy options have effectively improved dyspnea and quality of life. Recent studies have documented the benefits of pulmonary rehabilitation. In addition, noninvasive mechanical ventilation offers new alternatives for patients with acute or chronic failure. Furthermore, the revival of surgery for emphysema may serve as an alternative to lung transplantation for patients with severe COPD who remain symptomatic despite maximal medical therapy. With all of these options, a nihilistic attitude toward management of COPD is not justified.
Cote
Claudia G
CG
University of South Florida College of Medicine, Tampa, USA.
Celli
Bartolome R
BR
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D001993:Bronchodilator Agents / Q000627:therapeutic use; D018680:Cholinergic Antagonists / Q000627:therapeutic use; D005100:Expectorants / Q000627:therapeutic use; D006801:Humans; D010102:Oxygen Inhalation Therapy; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D022242:Pneumococcal Vaccines; D029424:Pulmonary Disease, Chronic Obstructive / Q000628:therapy*; D016540:Smoking Cessation
D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D000975:Antioxidants; D000998:Antiviral Agents; D001993:Bronchodilator Agents; D018680:Cholinergic Antagonists; D005100:Expectorants; D010726:Phosphodiesterase Inhibitors; D022242:Pneumococcal Vaccines